Shopping Cart 0
Cart Subtotal
AED 0

MEI Pharma Inc (MEIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

MEI Pharma Inc (MEI), formerly Marshall Edwards Inc is an oncology company that focuses on the development of drugs for the treatment of cancer. The company's drug candidates include pracinostat, an oral histone deacetylase inhibitor intended for the treatment of advanced hematologic diseases including acute myeloid leukemia and myelodysplastic syndrome; ME-344, an mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and ME-401, an oral PI3K delta inhibitor for B-cell malignancies, refractory chronic lymphocytic leukemia and follicular lymphoma. The company also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor through agreement with Presage. MEI is headquartered in San Diego, California, the US.

MEI Pharma Inc (MEIP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

MEI Pharma Acquires PWT143 From Pathway Therapeutics 12

MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To USD 76 Million 13

Private Equity 15

MEI Pharma to Raise USD75 Million in Private Placement of Shares 15

Partnerships 17

Helsinn Enters into Agreement with MEI Pharma 17

Licensing Agreements 18

MEI Pharma Enters into Licensing Agreement with Presage Biosciences 18

Helsinn Enters into Licensing Agreement with MEI Pharma 19

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 20

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 21

Equity Offering 22

MEI Pharma Plans to Raise Funds through Public Offering of Shares 22

MEI Pharma Raises USD46 Million in Public Offering of Shares 23

MEI Pharma Completes Public Offering Of Shares For USD 35 Million 25

MEI Pharma Completes Public Offering Of Shares For USD 15 Million 26

MEI Pharma Completes Private Placement Of Units For USD 27.5 Million 27

Marshall Edwards Completes Rights Offering Of Units For USD 5.2 Million 29

MEI Pharma Inc-Key Competitors 31

MEI Pharma Inc-Key Employees 32

MEI Pharma Inc-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

May 09, 2018: MEI Pharma Reports Third Quarter Fiscal Year 2018 Results 34

Feb 08, 2018: MEI Pharma Reports Second Quarter Fiscal Year 2018 Results 36

Nov 08, 2017: MEI Pharma Reports First Quarter Fiscal Year 2018 Results 38

Sep 05, 2017: MEI Pharma Reports Fiscal Year 2017 Results 39

May 04, 2017: MEI Pharma Reports Third Quarter Fiscal Year 2017 Results 41

Feb 08, 2017: MEI Pharma Reports Second Quarter Fiscal Year 2017 Results 42

Corporate Communications 44

Jul 16, 2018: MEI Pharma announces promotion of David M. Urso to chief operating officer 44

Feb 26, 2018: MEI Pharma Appoints Frederick W. Driscoll As Board Director 45

Apr 03, 2017: MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer 46

Product News 47

06/04/2018: MEI Pharma Presents Clinical Data for ME-344 in HER2 Negative Breast Cancer Patients at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 47

05/30/2018: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f 48

05/16/2018: MEI Pharma to Present Clinical Data on ME-344 at the 2018 ASCO Annual Meeting 49

05/16/2018: MEI Pharma to Present Clinical Data on ME-401 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 50

02/13/2018: MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer 51

Clinical Trials 52

Jun 15, 2018: MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress 52

Jun 04, 2018: MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 53

May 31, 2018: MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients 54

Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML) 56

Jan 08, 2018: MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib 57

Dec 21, 2017: MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports 58

Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 59

Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome 60

Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 61

May 31, 2017: MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma 62

May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 63

Other Significant Developments 64

Aug 30, 2018: MEI Pharma reports fiscal year 2018 results and operational highlights 64

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

MEI Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MEI Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

MEI Pharma Acquires PWT143 From Pathway Therapeutics 12

MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To USD 76 Million 13

MEI Pharma to Raise USD75 Million in Private Placement of Shares 15

Helsinn Enters into Agreement with MEI Pharma 17

MEI Pharma Enters into Licensing Agreement with Presage Biosciences 18

Helsinn Enters into Licensing Agreement with MEI Pharma 19

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 20

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 21

MEI Pharma Plans to Raise Funds through Public Offering of Shares 22

MEI Pharma Raises USD46 Million in Public Offering of Shares 23

MEI Pharma Completes Public Offering Of Shares For USD 35 Million 25

MEI Pharma Completes Public Offering Of Shares For USD 15 Million 26

MEI Pharma Completes Private Placement Of Units For USD 27.5 Million 27

Marshall Edwards Completes Rights Offering Of Units For USD 5.2 Million 29

MEI Pharma Inc, Key Competitors 31

MEI Pharma Inc, Key Employees 32

MEI Pharma Inc, Subsidiaries 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

MEI Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

MEI Pharma Inc (MEI), formerly Marshall Edwards Inc is an oncology company that focuses on the development of drugs for the treatment of cancer. The company's drug candidates include pracinostat, an oral histone deacetylase inhibitor intended for the treatment of advanced hematologic diseases including acute myeloid leukemia and myelodysplastic syndrome; ME-344, an mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and ME-401, an oral PI3K delta inhibitor for B-cell malignancies, refractory chronic lymphocytic leukemia and follicular lymphoma. The company also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor through agreement with Presage. MEI is headquartered in San Diego, California, the US.

MEI Pharma Inc (MEIP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

MEI Pharma Acquires PWT143 From Pathway Therapeutics 12

MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To USD 76 Million 13

Private Equity 15

MEI Pharma to Raise USD75 Million in Private Placement of Shares 15

Partnerships 17

Helsinn Enters into Agreement with MEI Pharma 17

Licensing Agreements 18

MEI Pharma Enters into Licensing Agreement with Presage Biosciences 18

Helsinn Enters into Licensing Agreement with MEI Pharma 19

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 20

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 21

Equity Offering 22

MEI Pharma Plans to Raise Funds through Public Offering of Shares 22

MEI Pharma Raises USD46 Million in Public Offering of Shares 23

MEI Pharma Completes Public Offering Of Shares For USD 35 Million 25

MEI Pharma Completes Public Offering Of Shares For USD 15 Million 26

MEI Pharma Completes Private Placement Of Units For USD 27.5 Million 27

Marshall Edwards Completes Rights Offering Of Units For USD 5.2 Million 29

MEI Pharma Inc-Key Competitors 31

MEI Pharma Inc-Key Employees 32

MEI Pharma Inc-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

May 09, 2018: MEI Pharma Reports Third Quarter Fiscal Year 2018 Results 34

Feb 08, 2018: MEI Pharma Reports Second Quarter Fiscal Year 2018 Results 36

Nov 08, 2017: MEI Pharma Reports First Quarter Fiscal Year 2018 Results 38

Sep 05, 2017: MEI Pharma Reports Fiscal Year 2017 Results 39

May 04, 2017: MEI Pharma Reports Third Quarter Fiscal Year 2017 Results 41

Feb 08, 2017: MEI Pharma Reports Second Quarter Fiscal Year 2017 Results 42

Corporate Communications 44

Jul 16, 2018: MEI Pharma announces promotion of David M. Urso to chief operating officer 44

Feb 26, 2018: MEI Pharma Appoints Frederick W. Driscoll As Board Director 45

Apr 03, 2017: MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer 46

Product News 47

06/04/2018: MEI Pharma Presents Clinical Data for ME-344 in HER2 Negative Breast Cancer Patients at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 47

05/30/2018: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f 48

05/16/2018: MEI Pharma to Present Clinical Data on ME-344 at the 2018 ASCO Annual Meeting 49

05/16/2018: MEI Pharma to Present Clinical Data on ME-401 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 50

02/13/2018: MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer 51

Clinical Trials 52

Jun 15, 2018: MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress 52

Jun 04, 2018: MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 53

May 31, 2018: MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients 54

Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML) 56

Jan 08, 2018: MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib 57

Dec 21, 2017: MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports 58

Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 59

Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome 60

Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 61

May 31, 2017: MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma 62

May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 63

Other Significant Developments 64

Aug 30, 2018: MEI Pharma reports fiscal year 2018 results and operational highlights 64

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

MEI Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MEI Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

MEI Pharma Acquires PWT143 From Pathway Therapeutics 12

MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To USD 76 Million 13

MEI Pharma to Raise USD75 Million in Private Placement of Shares 15

Helsinn Enters into Agreement with MEI Pharma 17

MEI Pharma Enters into Licensing Agreement with Presage Biosciences 18

Helsinn Enters into Licensing Agreement with MEI Pharma 19

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 20

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 21

MEI Pharma Plans to Raise Funds through Public Offering of Shares 22

MEI Pharma Raises USD46 Million in Public Offering of Shares 23

MEI Pharma Completes Public Offering Of Shares For USD 35 Million 25

MEI Pharma Completes Public Offering Of Shares For USD 15 Million 26

MEI Pharma Completes Private Placement Of Units For USD 27.5 Million 27

Marshall Edwards Completes Rights Offering Of Units For USD 5.2 Million 29

MEI Pharma Inc, Key Competitors 31

MEI Pharma Inc, Key Employees 32

MEI Pharma Inc, Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

MEI Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.